- Net income of Sun Pharma surpassed estimates with an impressive increase of 34% YOY to 26.5 billion rupees, compared to the estimated 24 billion rupees.
- The company recorded a revenue of 119.8 billion rupees, an increase of 9.6% YOY, though it fell short of the estimated revenue of 122.33 billion rupees.
- Indian sales constituted 37.08 billion rupees, slightly less than the projected 37.37 billion rupees.
- Revenue from the US totalled $476 million, just missing the estimated $489.4 million.
- Sun Pharma’s emerging markets revenue tallied $245 million, closely aligning with the prediction of $245.9 million.
- Rest of world sales brought in $196 million, less than the expected $212.3 million.
- The firm invested 9.00 billion rupees into research and development activities during the period.
- Its EBITDA reached 30.35 billion rupees, failing to meet the estimate of 32.34 billion rupees.
- The EBITDA margin was maintained at 25.3%.
- The company declared a dividend per share of 5 rupees.
- Lastly, the company has 32 buys, 6 holds, and 1 sell to its name.
A look at Sun Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead, Sun Pharmaceutical Industries appears to have a positive long-term outlook according to Smartkarma’s Smart Scores. With a strong score for Resilience, the company demonstrates stability and the ability to weather economic volatility. This is complemented by high scores for Dividend and Growth, indicating consistent returns to shareholders and potential for future expansion. Additionally, a solid Momentum score suggests that Sun Pharmaceutical Industries is well-positioned for continued growth in the pharmaceutical sector.
Sun Pharmaceutical Industries Limited, specializing in the manufacturing and distribution of pharmaceuticals both domestically and internationally, focuses on a diverse range of therapeutic areas including diabetes, cardiology, neurology, psychiatry, and gastroenterology. Given its promising Smart Scores across key factors, Sun Pharmaceutical Industries is poised for sustainable growth and value creation in the pharmaceutical industry over the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
